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ABSTRACT 
GABAA receptors containing the α5 subunit (α5GABAARs) are found mainly in the 
hippocampus where they mediate a tonic chloride leak current and contribute a slow component to 
GABAergic inhibitory synaptic currents. Their inhibitory effect on the excitability of hippocampal 
neurons at least partly explains why changes in the level of activity of α5GABAARs affect 
cognition, learning and memory. These receptors have been implicated as potential therapeutic 
targets for a range of clinical conditions including age-related dementia, stroke, schizophrenia, 
Down syndrome and anesthetic-induced amnesia. Accordingly, a range of pharmacological 
modulators that selectively target α5GABAARs, as either inhibitors or allosteric enhancers, have 
been developed. Although many of these compounds show therapeutic effects in animal models of 
the above clinical disorders, none has been marketed yet due to unsuccessful clinical trials and 
toxicity in humans. These experiments have also revealed paradoxical effects of α5GABAAR 
modulation (e.g., cognitive impairments can be reversed by both positive and negative modulation), 
suggesting that our knowledge of the physiological roles of α5GABAARs is incomplete. This review 
highlights the various positive and negative modulators for α5GABAARs that have been developed, 
key findings concerning their effects in behavioral studies, and their importance across a number of 
therapeutic fields. It also highlights some of the gaps in our knowledge of the physiological and 
pathological roles of α5GABAARs.  
 
GRAPHICAL ABSTRACT (n.b. a high resolution eps file of this image is attached as supp info) 
 
 
Fig. 1: Effects of positive allosteric modulator (PAM) and negative allosteric modulator (NAM) on GABA-
induced Cl- flow through GABAA receptors. (a) Binding of GABA to the receptor causes channel opening 
and Cl- influx. (b) PAM binds to the allosteric site to increase Cl- influx. (c) NAM reduces Cl- influx.  
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1. INTRODUCTION 
GABAA receptors (GABAARs) are the main inhibitory synaptic receptors in the central 
nervous system (CNS) [1]. As members of the pentameric ligand-gated ion channel family, 
functional GABAARs comprise five subunits arranged symmetrically around a central ion-
conducting pore. Each subunit consists of four α-helical transmembrane (TM) domains and a large 
extracellular amino-terminal domain that harbours the neurotransmitter binding sites and the 
signature ‘cysteine-loop’. Receptors are constructed from a family of 19 different subunits (α1-6, β1-
3, γ1-3, π, θ, ε, δ, andρ1-3) plus a few splice variants. The most common stoichiometry in vivo is two 
α, two β and one γ subunit [2, 3]. Subunit distribution varies developmentally and regionally across 
the brain, and within each brain region it varies according to cell type and subcellular localisation 
[4]. This variability underlies a broad range of GABAAR stoichiometries which in turn leads to a 
broad variation in inhibitory postsynaptic current kinetics, pharmacological profiles, subcellular 
targeting mechanisms and plasticity mechanisms that together provide appropriately nuanced 
influences on CNS network behavior.  
Due to the importance of GABAARs as therapeutic targets, the effects of subunit 
composition on their physiological roles and pharmacological profiles have been investigated 
intensively. For instance, studies on genetically modified mice have demonstrated that the widely 
distributed α1-containing GABAARs mediate the sedative and amnesic effects of the 
benzodiazepines (BZDs) whereas α2- and α3- containing receptors, located mainly in the forebrain, 
mediate their anticonvulsant and anxiolytic effects [2, 5]. The high density of α5-containing 
GABAARs (α5GABAARs) in the hippocampus suggests this subunit may be implicated in cognition, 
learning and memory [2, 6, 7]. In addition to the BZDs, other drugs or drug classes such as 
propofol, barbiturates and neurosteroids are also clinically important GABAAR modulators for 
indications including anaesthesia, anxiolysis, sedation or epilepsy. These drugs act mainly as 
positive modulators at the allosteric sites of GABAARs to enhance the effect of GABA. As they 
non-selectively target many GABAAR subtypes resulting in undesired side effects (including 
tolerance, sedation, anxiety and convulsion), many researchers are now focusing on designing or 
discovering new drugs that selectively target specific GABAAR subtypes. A major subtype of 
interest in this respect is the α5GABAAR.  
The α5GABAAR is of particular interest due to its interesting pharmacological benefits and 
its relatively sparse, compartmentalized CNS expression profile	   [4, 8]. For example, the locally 
high expression of α5GABAARs within hippocampal dendrites suggests that this subtype may be a 
useful target for therapies aimed at this part of the brain. Therapeutic interest in the α5GABAAR has 
extended to various disorders including stroke, cognitive enhancement, schizophrenia and 
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dementia-related conditions. This review will discuss the physiological properties, the 
pharmacological properties and the clinical significance of α5GABAARs and will then consider 
recent progress in the development of α5-selective compounds with different therapeutic utilities. 
The molecular structures, perceived clinical relevance and in vivo effects of all compounds 
discussed in this review are summarized in Table 1, whereas the pharmacological profiles of the 
compounds at α5GABAARs in vitro are presented in Table 2. 
 
2. PHYSIOLOGY 
 Although generally sparsely distributed, α5GABAARs are highly expressed not only in the 
hippocampus, but also in the olfactory bulb, neocortex, subiculum and substantia gelatinosa	   [8]. 
They display a high sensitivity to GABA and a slow desensitization rate	  [9]: properties which are 
well suited to mediating tonic inhibition in the presence of the low ambient GABA concentrations 
that exist outside the synapse. Indeed, it is now well established that α5GABAARs mediate most of 
the tonic inhibition in hippocampal neurons	  [10]. However, the evidence to date that α5GABAARs 
contribute significantly to fast transient inhibitory neurotransmission is somewhat less compelling. 
Although immunofluorescence has provided evidence for α5GABAAR clusters in neurons, they did 
not appear to be located at postsynaptic densities [11, 12]. On the other hand, an immunogold study 
presented evidence for both synaptic and non-synaptic localization of α5GABAARs [13]. 
Electrophysiological investigations of α5GABAAR-mediated synaptic currents in the hippocampus	  
suggest they contribute to a small, slow transient inhibitory component, but not to large, fast 
transient inhibition [9, 14-17], possibly implying a peri-synaptic localization of α5GABAARs [18]. 
 
3. SCHIZOPHRENIA 
 Antipsychotics are currently the first line treatment for schizophrenia. They are primarily 
used to treat the psychotic (or ‘positive’) symptoms, including hallucinations and delusions, 
experienced by schizophrenic patients. The negative symptoms, which include flattened expressions 
and lack of emotional responses, as well as the cognitive symptoms such as memory impairments, 
do not respond well to currently available antipsychotics. Moreover, debilitating side effects, such 
as agranulocytosis and seizures, can be caused by long-term use of the antipsychotics [19], 
highlighting the need for more effective treatments.  
Neuronal gamma oscillations (30-100 Hz) are important for cognitive processes including 
attention, arousal and object recognition, whereas oscillations in the theta range (4–10Hz) serve 
complementary cognitive functions, especially in particular episodic memory formation	   [20]. 
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Appropriate levels of tonic inhibition in the cortex and hippocampus are required to sustain these 
rhythms	   [21] and, as noted above, much of the tonic inhibition in these regions is provided by 
α5GABAARs. Disruptions in oscillatory activity (that could in principle be caused by any number of 
mechanisms) can lead to schizophrenia, and pharmacological manipulation of α5GABAARs is 
considered a promising means of normalizing these. Notably, a deficit in GABAergic 
neurotransmission has been shown to play a part in the pathology of schizophrenia, and several 
studies strongly indicate that expression levels of individual α subunits are altered in post-mortem 
brains of schizophrenic patients [22-25]. However, evidence implicating α5GABAARs has been 
elusive, with the expression of α5 shown to increase significantly in one study [25], with no change 
in another [26], while a third study saw a decline in α5 subunit expression [27, 28], suggesting the 
need for further clarification. Other studies have investigated the relationship between α5GABAAR 
expression and schizophrenia symptoms, and one, for instance, reported that the binding potential of 
[11C] Ro 15-4513, a benzodiazepine partial inverse agonist with relatively higher affinity for 
α5GABAARs, was inversely correlated with negative symptom scores in medication-free 
schizophrenic subjects [29]. Another study noted similarities in behavioral abnormalities between 
those seen in schizophrenia and in α5GABAAR knockdown mice, in particular a deficit in prepulse 
inhibition (PPI) to startle, in which the hippocampus is believed to play a role [30]. 
The DNA-methylating agent, methylaxozymethanol acetate (MAM), induces a 
developmental model of schizophrenia whereby affected animals exhibit both the structural and 
behavioral abnormalities that are normally seen in schizophrenia [31]. These animals were found to 
exhibit an increase in dopaminergic activity within the ventral tegmental area (VTA) that was 
thought to be due to hippocampal hyperactivity [32]. In a separate study, selective reduction of 
hippocampal tonic inhibition by knocking out α5 subunits in mice led to hyperactivity in the 
hippocampal network [10], suggesting that α5GABAAR deficiency could be one of the factors 
underlying the hyperdopaminergic activity seen in the schizophrenic mouse model. Hence, it was 
proposed that reducing hippocampal hyperactivity by using an α5GABAAR-selective positive 
modulator could be a novel therapeutic approach for schizophrenia [33]. This was investigated by 
monitoring of VTA neurons in MAM rats in the presence of SH-053-2’F-R-CH3 (Table 1, 2), a 
benzodiazepine α5-selective positive modulator [31]. This compound successfully diminished the 
number of spontaneously active dopaminergic neurons in the VTA in addition to reversing the 
heightened locomotor response to low dose of D-amphetamine in MAM but not in control rats [31], 
supporting the possible use of a similar treatment in schizophrenia. Given that inhibition of 
α5GABAARs enhances learning and memory	  [14, 34], it is feasible that an enhancer like SH-053-
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2’F-R-CH3 could produce anterograde memory impairment; however, no such memory impairment 
has been observed [35]. 
Paradoxically, however, the selective negative modulation of α5GABAARs by RO4938581 
(Table 1, 2) has also proved promising in reversing cognitive impairments in the phenylcyclidine-
induced schizophrenic rat model as well as in attenuating amphetamine-induced hyperactivity in 
rats [36]. This prompts the need for mechanistic studies to define the role of positive and negative 
α5GABAAR-selective modulators on neuron oscillatory behavior.  
 
4. NOOTROPIC 
A role for α5GABAARs in learning and memory has long been speculated due to its 
localization within the hippocampus. This hypothesis was first supported by a behavioral study, 
which saw significant improvement in the cognitive performance of α5 subunit-deficient mice 
compared to wild-type mice in the Morris water maze, a test of hippocampal-dependent spatial 
working memory [14]. Furthermore, reduced expression of α5 subunits in the mouse hippocampus 
was found to facilitate trace fear conditioning, a hippocampal-dependent associative learning 
paradigm [37, 38]. In light of this, it was hypothesized that selective negative modulators of 
α5GABAARs should enhance cognition while being devoid of side effects such as sedation and 
convulsion that result from modulation of other GABAAR subtypes. 
Among a series of novel benzodiazepine site ligands developed by Merck, Sharp and 
Dohme, the 6,7-dihydro-2-benzothiophen-4 (5H)-ones were found to exhibit high selectivity for α5, 
but low oral bioavailability. One compound of this class, Compound 43 (Table 1, 2), enhanced the 
cognitive performance of rats in the delayed matching-to-position (DMTP) version of the Morris 
water maze model without the anxiogenic or convulsive side effects typical of non-selective 
benzodiazepine receptor inverse agonists such as methyl-6, 7-dimethoxy-4-ethyl-beta-carboline-3-
carboxylate (DMCM) [39-42]. A similar result was observed with an orally administered 
α5GABAAR-selective pyrazolotriazine compound, MRK-016 (Table 1, 2), although this drug was 
discontinued because it was poorly tolerated in elderly subjects and exhibited unpredictable 
pharmacokinetics [43, 44]. Two structurally similar triazolophthalazines, α5IA and α5IA-II (Table 1, 
2), were also developed to be orally bioavailable and selective for α5GABAARs. These negative 
allosteric modulators that bind at the benzodiazepine site enhanced the performance of rodents in 
the DMTP water maze test without showing anxiogenic, sedative or convulsant effects [41, 45-47]. 
The cognition enhancing effect of α5IA-II was further substantiated in a behavioral study 
demonstrating a positive effect on the encoding and retrieval phases of memory and learning in rats 
[34]. Despite the promising outcomes of these trials, the development of these prototypes has been 
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discontinued. The nootropic effect of orally administered α5IA did not successfully translate into 
human clinical trials, as it not only failed to improve cognitive function in elderly subjects, but also 
significantly impaired their performance in a paired-associate learning task [46]. This was 
exacerbated by renal toxicity resulting from the accumulation of crystalline metabolites in the 
kidney [46]. Although both triazolophthalazines were devoid of convulsant side effects, α5IA-II, but 
not α5IA, was found to possess proconvulsant efficacy at high receptor occupancy owing to an 
observed potentiating effect on pentylenetetrazole-induced seizures in mice [41].  
Prior to the elucidation of the role of α5GABAARs in memory and learning, an 
imidazobenzodiazepine compound, L-655 708 (Table 1, 2), a negative allosteric modulator with 
high binding selectivity for α5GABAARs, had been developed for the purpose of investigating 
α5GABAAR structure and function [48, 49]. A behavioral study using the elevated plus-maze model 
later demonstrated that L-655 708 promoted an anxiogenic-like profile at doses required for 
efficacy [50], hence limiting the use of the drug as nootropic in humans even though it improved 
performance of mice in the Morris water maze [51]. Although L-655 708 binds with higher affinity 
to α5GABAARs, it also produces inverse agonist activity at other GABAAR subtypes (Table 2), and 
this is thought to contribute to its anxiogenic and possibly other side effects [49].  
Other notable α5GABAAR-selective negative modulators include RO4938581 and PWZ-029 
(Table 1, 2). Like other α5GABAAR negative modulators, the imidazo-triazolo-benzodiazepine 
RO4938581 managed to improve the cognitive performance of rats in the DMTP and Morris water 
maze models. In addition, RO4938581 enhanced the prefrontal executive function of cynomolgus 
monkeys in an object retrieval task without having any adverse effects on anxiety, convulsion, 
motor coordination or muscle strength [52, 53]. RO4938581 also significantly improved the 
performance of scopolamine- and diazepam-induced memory-impaired rats in the DMTP and 
Morris water maze, respectively [52, 53]. PWZ-029 is unusual in that it inhibits α5GABAARs at 
nanomolar concentrations but potentiates other GABAAR isoforms at much lower potencies [54, 
55]. In terms of memory-enhancing properties, orally administered PWZ-029 successfully improved 
the task learning of rats in a hippocampal-dependent passive avoidance test without producing 
anxiety or convulsions, although hypo-locomotion was observed at higher doses [55]. In a 
Pavlovian fear conditioning study, PWZ-029 notably reversed the scopolamine-induced impairment 
of contextual memory [54], in addition to improving the performance in novel object recognition 
test [56]. However, in contrast to most tested α5GABAAR negative modulators, PWZ-029 failed to 
improve cognitive performance in the Morris water maze model, either alone or in countering 
scopolamine-induced cognitive impairment in rats, prompting the need for further investigations to 
validate the cognition-enhancing properties of PWZ-029 [56].  
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5. NEURODEGENERATIVE CONDITIONS: ALZHEIMER’S DISEASE AND 
HUNTINGTON’S DISEASE 
Neurodegenerative diseases are characterized by progressive deficits in the structure and 
function of neurons leading to a combination of motor and cognitive decline. There is no effective 
cure for these diseases, which include Alzheimer’s and Huntington’s diseases, with currently 
available treatments being symptomatic and aimed at improving the quality of life of those affected.  
Post-mortem brains of Alzheimer’s disease (AD) patients have shown that, in addition to β-
amyloid plaques, neuronal network function in brain areas such as the cerebral cortex, brainstem 
and hippocampus is debilitated [57]. The loss of neurons in the hippocampus is partly due to the 
excessive stimulation of the excitatory synaptic glutamatergic receptors, which induces neuronal 
death [57]. Moreover, in both animal studies and neuroimaging of elderly individuals, age-related 
memory impairment has been shown to be associated with increased neural activity in the 
hippocampus [58-61]. On top of that, the number of inhibitory GABAergic interneurons in the 
hippocampus was found to be reduced in a mouse model that over-expresses apolipoprotein E4 
(apoE4), a well-known genetic risk factor for AD that leads to learning and memory deficits [62]. 
Initial interventions to counter the net excessive hippocampal activity included treatment with 
GABAAR non-selective positive modulator, pentobarbital, which successfully rescued spatial 
learning and memory deficits in apoE4-knock-in mice without affecting the number of hippocampal 
GABAergic interneurons [62]. However, chronic administration of pentobarbital led to numerous 
side effects, presumably due to non-specific effects on multiple GABAAR subtypes.  
Interestingly, various assays quantitating changes in protein, mRNA and ligand binding all 
showed that α5GABAAR expression in the hippocampus of human subjects with severe AD 
progression was distinctively lower compared to normal or mild AD individuals, although the 
precise mechanisms were poorly comprehended [63, 64]. As such, despite previous findings that 
negative modulators improve cognitive function, positive modulators that target α5GABAARs 
selectively are being investigated to restore hippocampal activity in aged brains. Using a rat model 
of age-related memory impairment, two distinct, but non-orally bioavailable, positive modulators of 
α5GABAARs, a benzothiophenone (compound 44) and a pyridazine (compound 6) (Table 1, 2), 
considerably improved hippocampal-dependent performance tasks, while a negative allosteric 
modulator had no effect in any of the tasks, further supporting the use of α5GABAAR positive 
modulators in age-related memory impairment [61]. 
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As with AD, patients with Huntington’s disease (HD) suffer from progressive cognitive 
decline. Experiments employing the R6/1 HD transgenic mouse model revealed that the disease’s 
hippocampal-dependent cognitive impairment could be partially due to an imbalance in the 
cholinergic/GABAergic septohippocampal (SH) neuronal projection [65, 66]. The SH projection is 
known to modulate the hippocampal theta oscillation important for memory formation and learning 
[67, 68], and abnormal hippocampal theta oscillation has indeed been demonstrated in humans with 
HD [69]. Therefore, restoring normal SH and oscillatory activities could be crucial for alleviating 
cognitive dysfunction in HD. As modulating α5GABAAR activity has been shown to restore 
hippocampal dysfunction, the same theory could possibly be extended to HD, although more studies 
are warranted to establish the role of α5GABAARs in HD.  
 
6. COGNITIVE DYSFUNCTION IN DOWN SYNDROME AND AUTISM 
 A majority of individuals with Down syndrome, or trisomy 21, exhibit mild to moderate 
cognitive dysfunction [70]. Exaggerated GABAergic activity in the hippocampus has been proposed 
to contribute to the memory and learning impairment in this disorder [21, 60, 71]. Consistent with 
this, the non-competitive GABAAR antagonist, pentylenetetrazole, improved cognitive performance 
in the segmentally trisomic Ts65Dn Down syndrome mice model [72], whereas picrotoxin 
effectively restored hippocampal long-term potentiation by non-selectively blocking GABAARs in 
the same animal model [71]. Nonetheless, as both pentylenetetrazole and picrotoxin have 
convulsant effects, their use has not translated into human clinical use. As an alternative, since 
α5GABAARs are well documented to be involved in cognition, it was thought that negative 
modulators targeting these receptors may reverse the cognitive dysfunction associated with this 
syndrome. The cognitive ability of Ts65Dn mice in both novel object recognition and Morris water 
maze tasks was indeed rescued by intraperitoneal injection of the inhibitor, α5IA [73]. The same 
compound was also reported to restore the expression of immediate early genes, namely the c-Fos 
and Arc genes, which regulate cognitive function in Ts65Dn mice [74]. Unfortunately, renal toxicity 
associated with the use of α5IA prevented its progression into clinical trials [46]. Nonetheless, 
inspired by the success of this finding, a separate study chronically treated the Ts65Dn mice with 
another α5GABAAR-selective negative modulator, RO4938581, and found a similar improvement 
in cognitive function, in addition to improvements in the hippocampal synaptic plasticity and adult 
neurogenesis. Furthermore, the hyperactive Ts65Dn mice were successfully calmed by RO4938581 
without producing any adverse convulsant, motor or anxiety effects [75]. At present, Hoffman-La 
Roche is sponsoring several Phase 1 clinical trials of RG 1662, an analogue of RO4938581, in 
young healthy and Down syndrome adults.  
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As with Down syndrome, children diagnosed with autism spectrum disorder (ASD) may 
also experience impairments in hippocampal-dependent learning and memory [76]. However, 
unlike Down syndrome, it is the excessive neural activity, leading to excitatory/inhibitory 
imbalance in the brain, that has been implicated with the neuropathological characteristics of ASD 
[21, 77]. This was further reinforced when antiepileptic drugs used in ASD patients meant to relieve 
partial seizures inexplicably improved cognitive function in some individuals [60]. Also, low doses 
of the non-selective benzodiazepine, clonazepam, managed to rescue abnormal social behaviours 
and cognitive deficits in the Scn1a+/- mice model of Dravet’s syndrome, a syndromic form of ASD 
[78]. Considering that selective α5GABAAR negative modulators successfully reduced excessive 
hippocampal tonic inhibition in animal models to regain cognitive ability, perhaps the same 
principle can be applied to ASD in future studies. 
 
7. STROKE 
Stroke is consistently ranked as one of the leading causes of death. Long-term functional 
and cognitive disabilities often persist following stroke, which in turn negatively affect the patient’s 
employability and quality of life. The area adjacent to the stroke site, the peri-infarct area, has been 
demonstrated to undergo poorly understood mechanisms of neuronal repair by means of 
neurogenesis, axonal sprouting and remapping of cognitive functions in order to regain functional 
and cognitive abilities [18, 79-81]. These changes are not only slow, but currently available 
medications are mainly preventatives for recurrent stroke (e.g., anticoagulants, antihypertensives) 
and do not facilitate brain repair or recovery following the stroke, prompting the need for more 
effective stroke treatments. 
 There is evidence for augmented GABAergic tonic inhibition in the peri-infarct region of 
cortical pyramidal neurons at a time delay of 3 to 14 days post-stroke [18, 82]. It has been proposed 
that although enhanced tonic inhibition at the time of stroke is necessary to limit further neuronal 
injury, a persistent increase in tonic inhibition may deter proper neuronal repair and functional 
recovery [18]. Hence, it was thought that attenuating GABAergic tonic inhibition, starting at day 3 
after the onset of stroke, could help in promoting neuronal and functional recovery. Additionally, 
post-stroke brain recovery is drastically improved by stimulating the learning and memory pathway, 
in which the α5GABAAR plays an important role [82, 83]. Recent evidence showed that chronic 
treatment with the α5-selective negative modulator, L-655 708, starting from the third day following 
stroke in a mouse model, significantly improved functional recovery that was evident from the 
seventh day post-stroke whereas acute treatment had negligible effect on recovery [82]. Not only 
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that, knockout of the α5GABAAR also boosted the rate of motor recovery in post-stroke mice, the 
effect comparable to the group that was administered with L-655 708 [14, 82]. On a cellular level, 
nanomolar L-655 708 successfully diminished GABAergic tonic inhibitory currents both in control 
and post-stroke neurons, albeit more conspicuously in post-stroke neurons, further substantiating 
the implication of α5GABAARs in stroke and possibly other types of brain injuries [82]. It is 
noteworthy that best outcomes were achieved several days after the stroke because it implies it may 
be feasible to develop treatments that work at delayed time points when options for early 
intervention have been missed. 
 
8. PREVENTION OF AMNESIA 
Postoperative Cognitive Dysfunction (POCD), or memory deficits occurring post-surgery, is 
common especially in elderly patients after major surgery and is caused by the after-effects of 
anesthetic administration. POCD has been reported to persist for up to three months following 
surgery, and in addition POCD patients are predisposed to increased risk of death in the first year 
after surgery [84, 85]. The mechanisms underlying POCD remain controversial, although the high 
expression level of α5GABAARs in the hippocampus is thought to play a part in mediating the 
amnesic side effects of anesthetics [86, 87]. This notion is supported by several electrophysiological 
and behavioral studies showing that low concentrations of isoflurane and etomidate selectively 
potentiate α5GABAARs in hippocampal pyramidal neurons to mediate the memory-blocking effect 
of anesthetics [9, 86-88]. In a separate study, α5GABAAR-knockout mice were resistant to the 
memory-blocking effect of inhaled isoflurane and sevoflurane, further substantiating the role of 
α5GABAARs in POCD [89]. Thus, it was hypothesized that administering a negative modulator of 
α5GABAARs pre-surgery might mitigate the post-anesthesia amnesic side effect. Consistent with 
this idea, animal behavioral studies demonstrated that pre-treatment with the α5GABAAR negative 
modulator, L-655 708, was indeed able to reverse short- and long-term memory impairment in mice 
anesthetized with isoflurane [87, 89]. Furthermore, L-655 708 and another α5GABAAR-selective 
negative allosteric modulator, MRK-016 (Table 1, 2), significantly inhibited isoflurane and 
sevoflurane-potentiated GABA currents in hippocampal neurons of wild-type mice, whereas the 
GABA response in α5GABAAR-knockout mice was not affected by the anesthetics [90]. On a 
related matter, pre-treatment with α5IA in human subjects managed to selectively counter the 
deterioration in the ability to recall a word list following alcohol consumption [46, 91]. Hence, it 
seems possible that the applicability of α5GABAAR-selective negative modulators may extend to 
other amnestic disorders, especially in light of a study which showed that hippocampal GABAARs 
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also play a role in Wernicke-Korsakoff syndrome, a type of diencephalic amnesia attributed to 
vitamin B1 deficiency [92].  
 
9. DRUG DISCOVERY STRATEGIES 
 This review has highlighted the need for new drugs that specifically modulate α5GABAARs 
as therapeutic leads for a variety of clinical indications. What strategies can be used to discover 
such drugs? Here we briefly consider two points related to identifying new lead candidates. The 
first point relates to the chemical diversity to be screened. Over the last 20 years, major 
pharmaceutical companies have focused more on probing the artificial chemical diversity that can 
be generated via combinatorial chemistry, and less on the natural chemical biodiversity found in 
natural products [93]. If the number of drugs reaching the clinic is the yardstick, it must be 
concluded that this approach has not worked. This is considered to be largely due to the limited 
structural diversity inherent in conventional combinatorial libraries, and indeed has prompted 
renewed interest in the development of drugs from natural sources [93-95]. However, natural 
product drug discovery has its limitations too, including difficulties with the resupply of raw 
materials, difficulties with the repeated isolation of known compounds, and difficulties with 
synthesizing natural compounds of interest [94]. More recently, hybrid approaches have been 
developed whereby combinatorial libraries incorporate the broader chemical diversity of natural 
products [96, 97]. When coupled with complementary approaches such as fragment-based 
discovery [98], diversity-orientated synthesis [99], and dynamic combinatorial chemistry [100], the 
potential for generating new generations of α5GABAAR-specific modulators looks promising.  
The second issue relates to the choice of methods of screening compound libraries against 
GABAAR subtypes. This involves a trade-off between the low cost and high throughput of 
fluorescent assays (notably voltage-sensitive dyes or yellow fluorescent protein) and the precision 
and temporal resolution of patch-clamp electrophysiology [101, 102]. Although automated patch-
clamp technologies are advancing steadily in throughput and cost, electrophysiology is not yet a 
viable means of first round high-throughput screening. The approach we recommend is to perform 
initial screening via a fluorescence assay, with confirmatory screening and validation of successful 
hits by high throughput electrophysiology [103, 104]. 
 
CONCLUSION 
Compounds that selectively target α5GABAAR, as either positive or negative modulators, 
are of utmost importance clinically as they have the potential for treating a range of CNS disorders. 
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For example, positive allosteric modulators for α5GABAARs hold promise as new generation 
treatments for schizophrenia and age-related cognitive impairments, whereas negative allosteric 
modulators may be useful as nootropics and as treatments for conditions like Down syndrome, 
stroke and amnestic disorders. Although a number of α5GABAAR-selective compounds have been 
identified, none have yet reached the clinic due to toxicity, lack of efficacy, side effect profiles and 
unpredictable pharmacokinetics in humans. This highlights the need for further research to identify 
new α5-selective ligands with better efficacy as well as safer pharmacological and pharmacokinetic 
profiles in humans. Subunit specific compounds can also be used as pharmacological probes to 
understand the basic neural mechanisms of the aforementioned diseases.  
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Table 1: Structure of α5GABAAR-selective positive and negative modulators, their functional 
relevance and summary of the key findings from previous studies. 
Positive 
modulator 
Compound structure Function/ 
disease 
relevance 
Key findings 
SH-053-2’F-R-
CH3 ((R)-8-
ethynyl-6-(2-
fluorophenyl)-4-
methyl-4H-
2,5,10b-triaza-
benzo[e]azulene-3-
carboxylic acid 
ethyl ester) 
 
 
 
 
Schizophrenia Advantages 
- Reduced spontaneously active 
dopaminergic neurons in VTA [31] 
- Reduced locomotor response to low 
dose of D-amphetamine in MAM-
induced schizophrenic rat model [31] 
- No effect on visual recognition and 
spatial working memory in rhesus 
monkeys [35] 
- Non-sedating in primates [105] 
Disadvantages 
- Not orally bioavailable, dosed 
intravenously [105] or intraperitoneally 
[106] 
- No data on toxicity 
Compound 44 
(6,6-dimethyl-3-(3-
hydroxypropyl)thi
o1-(thiazol-2-yl)-
6,7-dihydro-2-
benzothiophen-
4(5H)-one) 
 
 
 
Alzheimer’s 
disease 
Advantages 
- Improved escape performance of aged 
rats in water maze task [61] 
Disadvantages 
- Not orally bioavailable, drug was 
administered by intracerebroventricular 
infusion [61] 
- No data on toxicity  
Compound 6 
(methyl 3,5-
diphenylpyridazine
-4-carboxylate) 
 
 
 
Alzheimer’s 
disease 
Advantages 
- Improved spatial memory of aged rats in 
radial arm maze test [61] 
- Treatment in young rats had no effect on 
cognitive performance [61] 
Disadvantages 
- Not orally bioavailable, drug was 
injected intraperitoneally [61] 
- Toxicity data not available 
Negative 
modulator 
Compound structure Function/ 
disease 
relevance 
Key findings 
Compound 43 
(6,6-Dimethyl-3-
(2-hydroxyethyl)th
io1-(thiazol-2-yl)-
6,7-dihydro-2-
benzothiophen-
4(5H)-one) 
 
 
 
Nootropic Advantages 
- Enhanced cognitive performance of 
normal rats in DMTP water maze [39] 
- Not anxiogenic and convulsant in 
animal models [39] 
MRK-016 (3-tert-  Nootropic - Improved performance of normal rats in 
N
N
N
F
O
CH3
HC
CH3
O
N
S S
O
CH3
H3C
S OH
N
N
O
CH3
O
S S
OH
S
N
H3C
CH3
O
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butyl-7-(5-
methylisoxazol-3-
yl)-2-(1-methyl-
1H-1,2,4-triazol-5-
ylmethoxy)-
pyrazolo[1,5-d]-
[1,2,4]triazine) 
 
 
 
 
DMTP water maze [40] 
- Neither anxiogenic, proconvulsant nor 
produce kindling in mice [44] 
- Orally bioavailable [44] 
- Well tolerated in healthy young subjects 
[44] 
Disadvantages 
- Effect on improving cognitive function 
in human subjects not evaluated [44] 
- Poorly tolerated in elderly subjects with 
unpredictable pharmacokinetics [44] 
Postoperative 
cognitive 
dysfunction 
Advantages 
- Inhibited isoflurane and sevoflurane-
potentiated GABA currents in wild-type 
mice hippocampal neurons [90] 
α5IA (1,2,4-
Triazolo[3,4-
a]phthalazine, 3-
(5-methyl-3-
isoxazolyl)-6-[(1-
methyl-1H-1,2,3-
triazol-4-
yl)methoxy]-, 3-(5-
Methylisoxazol-3-
yl)-6-(1-methyl-
1,2,3-triazol-4-
yl)methoxy-1,2,4-
triazolo[3,4-
a]phthalazine) 
 
 
 
 
 
 
 
 
 
 
Nootropic Advantages 
- Enhanced performance of rodents in 
DMTP water maze at 40% receptor 
occupancy [41] 
- Not anxiogenic, sedative and convulsant 
in animal models [41] 
- Orally bioavailable [41, 46] 
Disadvantages 
- Impairs performance of elderly human 
subjects in paired-associate learning task 
[46] 
- Short half-life [46] 
Down 
syndrome 
Advantages 
- Rescued cognitive ability of Ts65Dn 
Down syndrome mice model in novel 
object recognition and Morris water 
maze model [73] 
- Restored immediate early gene 
expression related to cognitive function 
in Down syndrome mice [74] 
Disadvantages 
- Formation of crystalline metabolite with 
low solubility resulted in renal toxicity 
in human subjects [46] 
- Long-term dosing necessary for clinical 
efficacy cannot be achieved [46] 
Alcohol-
induced 
amnesia 
Advantages 
- Oral pre-treatment prevented negative 
effect of alcohol on the ability to recall 
word list in human subjects [46, 91] 
α5IA-II (3-(5-
Methylisoxazol-3-
yl) -6-(2- pyridyl) 
methyloxy- 1,2,4-
triazolo [3,4-a] 
 Nootropic Advantages 
- Oral dosing available [47] 
- Enhanced performance of rodents in 
DMTP water maze [47] 
- Not anxiogenic, sedative and convulsant 
O N
N
N
N
N
O
N
N
NH3C
CH3
CH3
CH3
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phthalazine) 
 
in animal models[47] 
- Improved encoding and retrieval phases 
of memory and learning in rats [34] 
Disadvantages 
- Proconvulsant at high doses [47] 
- No data on toxicity 
L-655 708 
(ethyl (13aS)-7-
methoxy-9-oxo-
11,12,13,13a-
tetrahydro-9H-
imidazo [1,5-
a]pyrrolo[2,1 
c][1,4]benzodiazep
ine-1-carboxylate) 
 
 
 
 
 
 
 
 
 
 
 
Nootropic Advantages 
- Improved performance of mice during 
acquisition and consolidation phases in 
Morris water maze model [51] 
Disadvantages 
- Not orally bioavailable 
- Anxiogenic at doses required to enhance 
cognition [50] 
- Although with high affinity for 
α5GABAAR, negative modulation at 
other GABAAR subtypes may lead to 
unwanted side effects [51] 
- Toxicity data unknown 
Recovery 
from stroke 
Advantages 
- Chronic treatment a delay after stroke 
onset improved functional recovery 
from stroke [82] 
- Diminished GABAergic tonic inhibitory 
currents more conspicuously in post-
stroke neurons [82] 
Disadvantages 
- Drug was implanted (chronic) or 
administered intraperitoneally (acute) 
[82] 
Postoperative 
cognitive 
dysfunction 
Advantages 
- Blocked short- and long-term memory 
impairment induced by anaesthetics in 
mice [87, 89] 
- Inhibited GABA responses enhanced by 
isoflurane and sevoflurane in mice 
hippocampal neurons [89] 
RO4938581 
((3-Bromo-10-
difluoromethyl- 
9H-imidazo[1,5-a] 
[1,2,4] 
triazolo[1,5-d] 
[1,4] 
benzodiazepine) 
 
 
 
 
 
 
Schizophrenia Advantages 
- Improved cognitive impairment in PCP-
induced schizophrenic rat model [36] 
- Reduced amphetamine-induced 
hyperactivity in rats [36] 
- Has both binding and functional 
selectivity [52, 53] 
Disadvantages 
- No data on toxicity 
Nootropic Advantages 
- Enhanced cognitive performance of 
normal rats in DMTP task and Morris 
N
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water maze model [52, 53]  
- Enhanced prefrontal executive function 
of cynomolgus monkeys in object 
retrieval task [52] 
- Only 30% receptor occupancy needed to 
enhance cognition in animal model [52] 
- Orally bioavailable [36, 52] 
- No effect on anxiety, convulsion, motor 
coordination or muscle strength [53] 
- Reversed scopolamine- and diazepam-
induced memory impairment of rats in 
DMTP and Morris water maze [52, 53]  
Down 
syndrome 
Advantages 
- Long-term treatment improved cognitive 
impairment in Ts65Dn Down syndrome 
mice model [75] 
- Improved hippocampal synaptic 
plasticity and neurogenesis [75] 
- Reduced hyperactivity tendency in 
Ts65Dn mice [75] 
- A structurally related compound, RG 
1662, is currently in clinical trials to 
treat cognitive impairments associated 
with Down syndrome 
PWZ-029 (8-
chloro-3-
(methoxymethyl)-
5-methyl-4H-
imidazo[1,5-
a][1,4]benzodiazep
in-6-one) 
 
 
 
 
Nootropic Advantages 
- Improved the task learning of rats in 
passive avoidance test [55] 
- No effect on anxiety or convulsions [55] 
- Reversed scopolamine-induced memory 
impairment in Pavlovian fear 
conditioning in mice model [54] 
- Improved performance of rodents in 
novel object recognition test [56] 
Disadvantages 
- Hypo-locomotion observed in rodents at 
higher receptor occupancy [55] 
- Failed to improve cognitive performance 
of rats in Morris water maze [56] 
 
Table 2: In vitro selectivity profile (affinity vs efficacy) of modulators at αxβ3γ2 GABAAR 
subtypes.  
Modulator Binding affinity (Ki, nM); % modulationa Reference 
α1 α2 α3 α5 
Diazepam 14.0; 239 (at 
100 nM), 314 (at 
1 µM) 
7.8; 426 (at 
100 nM), 536 (at 
1 µM) 
13.9; 437 (at 
100 nM), 752 (at 
1 µM) 
13.4; 274 (at 
100 nM), 342 (at 
1 µM) 
[105] 
SH-053-2’F-R-
CH3 
759.1; 111 (at 
100 nM), 154 (at 
1 µM) 
948.2; 124 (at 
100 nM), 185 (at 
1 µM) 
768.8; 125 (at 
100 nM), 220 (at 
1 µM) 
95.2; 183 (at 
100 nM), 387 (at 
1 µM) 
[105, 106] 
Compound 44  79; NA 48; NA 48; NA 4.7; 25b [40] 
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Compound 6  154; NA NA; NA 64; NA 12; 27 (at 300 nM) [107] 
Compound 43  20; NA 16; NA 20; NA 1.6; -38b [40] 
MRK-016 0.83; 
-16b 
0.85; 
6b 
0.77; 
-9b 
1.36; 
-55b 
[44] 
α5IA 0.88; -4b 0.58; 12b 0.61; 4b 0.66; -29b [41, 45] 
α5IA-II 0.93; -2b 1.5; 15b 0.96; -4b 0.62; -46b [41, 47] 
L-655 708 70; -18b 48; -23b 31; -11b 1.0; -17b [51] 
RO4938581 174; -3c 185; -4c 80; 2c 4.6; -35c [52, 53] 
PWZ-029 >300; 114 (at 
1 µM), 120 (at 
10 µM) 
>300; 105 (at 
1 µM), 115 (at 
10 µM) 
>300; 118 (at 
1 µM), 145 (at 
10 µM) 
38.8; -20 (at 
1 µM), -20 (at 10 
µM) 
[55] 
a Efficacy is determined as % of control currents from electrophysiology experiments. 
b Value represents % modulation of GABA EC20 concentration. 
c Value represents % modulation of GABA EC10 concentration. 
NA Data not available. 
	  
